Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Scott Weir, Risa Torkin & Herbert R. Henney III. (2013) Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29:12, pages 1627-1636.
Read now
Read now
Sheryl R. Haut, E. Jay Bienen & Aaron Miller. (2012) Clinical overview of the seizure risk of dalfampridine
. Expert Opinion on Drug Safety 11:4, pages 651-657.
Read now
Read now
Keith C Hayes. (2011) Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7, pages 229-239.
Read now
Read now
Hillel Panitch & Angela Applebee. (2011) Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opinion on Pharmacotherapy 12:10, pages 1511-1521.
Read now
Read now
Jeffrey Dunn & Andrew Blight. (2011) Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current Medical Research and Opinion 27:7, pages 1415-1423.
Read now
Read now
Keith C Hayes. (2007) Fampridine-SR for multiple sclerosis and spinal cord injury. Expert Review of Neurotherapeutics 7:5, pages 453-461.
Read now
Read now
Yesim Tuncok, Sebnem Apaydin, Ayse Gelal, Mehmet Ates & Hulya Guven. (1998) The Effects of 4-Aminopyridine and Bay K 8644 on Verapamil-Induced Cardiovascular Toxicity in Anesthetized Rats. Journal of Toxicology: Clinical Toxicology 36:4, pages 301-307.
Read now
Read now
Winai Wananukul, Daniel E. Keyler & Paul R. Pentel. (1996) Effect of Calcium Chloride and 4-Aminopyridine Therapy on Desipramine Toxicity in Rats. Journal of Toxicology: Clinical Toxicology 34:5, pages 499-506.
Read now
Read now
Articles from other publishers (41)
Ashwini Sri Hari, Rajeswari Banerji, Li-Ping Liang, Ruth E. Fulton, Christopher Quoc Huynh, Timothy Fabisiak, Pallavi Bhuyan McElroy, James R. Roede & Manisha Patel. (2023) Increasing glutathione levels by a novel posttranslational mechanism inhibits neuronal hyperexcitability. Redox Biology 67, pages 102895.
Crossref
Crossref
Guan‐Hsun Wang, Ai‐Yu Chuang, Yi‐Chen Lai, Hsin‐I Chen, Shu‐Wei Hsueh & Ya‐Chin Yang. (2022)
Pre‐synaptic and post‐synaptic A‐type K
+
channels regulate glutamatergic transmission and switching of the network into epileptiform oscillations
. British Journal of Pharmacology 179:14, pages 3754-3777.
Crossref
Crossref
Eveline Van Looy, Annelies Van Dycke & Ludo Vanopdenbosch. (2021) Two related cases of super‐refractory status epilepticus due to 4‐aminopyridine intoxication and an overview of the literature. Epileptic Disorders 23:3, pages 527-530.
Crossref
Crossref
Lauren K. Shawn. 2017. Case Studies in Medical Toxicology. Case Studies in Medical Toxicology
181
187
.
Philippe E. Hantson. 2017. Critical Care Toxicology. Critical Care Toxicology
447
473
.
Philippe E. Hantson. 2016. Critical Care Toxicology. Critical Care Toxicology
1
27
.
Andrew R. Blight, Herbert R. HenneyIIIIII & Ron Cohen. (2014) Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences 1329:1, pages 33-44.
Crossref
Crossref
Anne-Michelle Ruha & Michael Levine. (2014) Central Nervous System Toxicity. Emergency Medicine Clinics of North America 32:1, pages 205-221.
Crossref
Crossref
Maria Ballesta M?ndez, Vincent van Pesch, Arnaud Capron & Philippe Hantson. (2014) Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. Case Reports in Neurological Medicine 2014, pages 1-4.
Crossref
Crossref
Saurabh K. Sinha & Sushant K. Shrivastava. (2013) Design, synthesis and evaluation of some new 4-aminopyridine derivatives in learning and memory. Bioorganic & Medicinal Chemistry Letters 23:10, pages 2984-2989.
Crossref
Crossref
Saurabh K. Sinha & Sushant K. Shrivastava. (2012) Synthesis and evaluation of some new 4-aminopyridine derivatives as a potent antiamnesic and cognition enhancing drugs. Medicinal Chemistry Research 21:12, pages 4395-4402.
Crossref
Crossref
Andrew M. King, Nathan B. Menke, Kenneth D. Katz & Anthony F. Pizon. (2012) 4-Aminopyridine Toxicity: a Case Report and Review of the Literature. Journal of Medical Toxicology 8:3, pages 314-321.
Crossref
Crossref
Saam Sedehizadeh, Michael Keogh & Paul Maddison. (2012) The Use of Aminopyridines in Neurological Disorders. Clinical Neuropharmacology 35:4, pages 191-200.
Crossref
Crossref
David R. Cornblath, E. Jay Bienen & Andrew R. Blight. (2012) The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials. Clinical Therapeutics 34:5, pages 1056-1069.
Crossref
Crossref
Riyi Shi & Wenjing Sun. (2011) Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons钾通道阻滞剂可以有效修复受伤轴突的冲动传导. Neuroscience Bulletin 27:1, pages 36-44.
Crossref
Crossref
M.A. Sahraian, A.H. Maghzi, M. Etemadifar & A. Minagar. (2011) Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis. Journal of Central Nervous System Disease 3, pages JCNSD.S4868.
Crossref
Crossref
Gary Leung, Wenjing Sun, Sarah Brookes, Daniel Smith & Riyi Shi. (2011) Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis. Experimental Neurology 227:1, pages 232-235.
Crossref
Crossref
A. L. Hopkins & J. Clarke. (2010) Episodic cerebellar dysfunction in a bichon frise: a canine case of episodic ataxia?. Journal of Small Animal Practice 51:8, pages 444-446.
Crossref
Crossref
Andis Graudins & Kathy Ka Ling Wong. (2010) Comparative Hemodynamic Effects of Levosimendan Alone and in Conjunction with 4-Aminopyridine or Calcium Chloride in a Rodent Model of Severe Verapamil Poisoning. Journal of Medical Toxicology 6:2, pages 85-93.
Crossref
Crossref
William Smith, Suzanne Swan, Thomas Marbury & Herbert HenneyIIIIII. (2013) Single‐Dose Pharmacokinetics of Sustained‐Release Fampridine (Fampridine‐SR) in Healthy Volunteers and Adults With Renal Impairment. The Journal of Clinical Pharmacology 50:2, pages 151-159.
Crossref
Crossref
Wenjing SunDaniel Smith, Yan Fu, Ji-Xin Cheng, Steven Bryn, Richard Borgens & Riyi Shi. (2010) Novel Potassium Channel Blocker, 4-AP-3-MeOH, Inhibits Fast Potassium Channels and Restores Axonal Conduction in Injured Guinea Pig Spinal Cord White Matter. Journal of Neurophysiology 103:1, pages 469-478.
Crossref
Crossref
Craig Smith, Sathapana Kongsamut, Hongge Wang, Junzhi Ji, Jiesheng Kang & David Rampe. (2009)
In Vitro
electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivative
. Clinical and Experimental Pharmacology and Physiology 36:11, pages 1104-1109.
Crossref
Crossref
N. J. OLBY, D. T. SMITH, J. HUMPHREY, K. SPINAPOLICE, N. PARKE, P. M. MEHTA, D. DISE & M. PAPICH. (2009) Pharmacokinetics of 4-aminopyridine derivatives in dogs. Journal of Veterinary Pharmacology and Therapeutics 32:5, pages 485-491.
Crossref
Crossref
Timothy Vollmer & Herbert R. HenneyIIIIII. (2009) Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial. Clinical Therapeutics 31:10, pages 2206-2214.
Crossref
Crossref
Timothy Vollmer, Andrew R. Blight & Herbert R. HenneyIIIIII. (2009) Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study. Clinical Therapeutics 31:10, pages 2215-2223.
Crossref
Crossref
Wenjing Sun, Daniel Smith, Steven Bryn, Richard Borgens & Riyi Shi. (2009) N-(4-pyridyl) methyl carbamate inhibits fast potassium currents in guinea pig dorsal root ganglion cells. Journal of the Neurological Sciences 277:1-2, pages 114-118.
Crossref
Crossref
Kiyoaki Kobayashi, Yukio Nishizawa, Kohei Sawada, Hiroo Ogura & Masayuki Miyabe. (2008) K+-Channel Openers Suppress Epileptiform Activities Induced by 4-Aminopyridine in Cultured Rat Hippocampal Neurons. Journal of Pharmacological Sciences 108:4, pages 517-528.
Crossref
Crossref
J.M. McBride, D.T. Smith, S.R. Byrn, R.B. Borgens & R. Shi. (2007) 4-Aminopyridine derivatives enhance impulse conduction in guinea-pig spinal cord following traumatic injury. Neuroscience 148:1, pages 44-52.
Crossref
Crossref
A. N. Boiko, T. T. Batysheva, O. V. Matvievskaya, T. M. Manevich & E. I. Gusev. (2007) Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage. Neuroscience and Behavioral Physiology 37:3, pages 221-228.
Crossref
Crossref
Susan I.V. Judge & Christopher T. BeverJr.Jr.. (2006) Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacology & Therapeutics 111:1, pages 224-259.
Crossref
Crossref
Nicholas C. Johnson & Matthew W. Morgan. (2006) An unusual case of 4-aminopyridine toxicity. The Journal of Emergency Medicine 30:2, pages 175-177.
Crossref
Crossref
Keith C. Hayes. (2006) The Use of 4‐Aminopyridine (Fampridine) in Demyelinating Disorders. CNS Drug Reviews 10:4, pages 295-316.
Crossref
Crossref
ERICA ANDERSON McELROY & ERICA L. LIEBELT. (2003) Toxic seizures in children. Pediatric Emergency Care 19:3, pages 206-210.
Crossref
Crossref
K. C. Hayes, M. A. Katz, J. G. Devane, J. T. C. Hsieh, D. L. Wolfe, P. J. Potter & A. R. Blight. (2003) Pharmacokinetics of an Immediate-Release Oral Formulation of Fampridine (4-Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury. The Journal of Clinical Pharmacology 43:4, pages 379-385.
Crossref
Crossref
Larissa Velez, Farshad Shirazi, Collin Goto, Greene Shepherd & Brett A. Roth. (2003) Opisthotonic Posturing With Neuromuscular Irritability Attributable to 4-Aminopyridine Ingestion by a Healthy Pediatric Patient. Pediatrics 111:1, pages e82-e84.
Crossref
Crossref
D.L. Wolfe, K.C. Hayes, J.T.C. Hsieh & P.J. Potter. (2001) Effects of 4-Aminopyridine on Motor Evoked Potentials in Patients with Spinal Cord Injury: A Double-Blinded, Placebo-Controlled Crossover Trial. Journal of Neurotrauma 18:8, pages 757-771.
Crossref
Crossref
Jack L. Segal MD, Keith C. Hayes, Sherry R. Brunnemann, Jane T. C. Hsieh, Patrick J. Potter, Mayank S. Pathak, David S. Tierney & David Mason. (2013) Absorption Characteristics of Sustained‐Release 4‐Aminopyridine (Fampridine SR) in Patients with Chronic Spinal Cord Injury. The Journal of Clinical Pharmacology 40:4, pages 402-409.
Crossref
Crossref
P. J. POTTER, K. C. HAYES, J. L. SEGAL, J. T. C. HSIEH, S. R. BRUNNEMANN, G.A. DELANEY, D. S. TIERNEY & D. MASON. (1998) Randomized Double-Blind Crossover Trial of Fampridine-SR (Sustained Release 4-Aminopyridine) in Patients With Incomplete Spinal Cord Injury. Journal of Neurotrauma 15:10, pages 837-849.
Crossref
Crossref
Tracy A Pickett & Robert Enns. (1996) Atypical Presentation of 4-Aminopyridine Overdose. Annals of Emergency Medicine 27:3, pages 382-385.
Crossref
Crossref
Christopher T. BeverJr.Jr.. (2006) 4‐Aminopyridine: Use in Multiple Sclerosis. CNS Drug Reviews 1:2, pages 261-279.
Crossref
Crossref
&NA;. (1994) Aminopyridine overdose. Reactions Weekly &NA;:529, pages 4.
Crossref
Crossref